Skip to main content
Signal8
Launch Terminal

Indivior Pharmaceuticals, Inc. (INDV)

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Indivior Pharmaceuticals Inc logo

Indivior Pharmaceuticals Inc

NASDAQ:INDVHealthcare
+0.34%$35.37
AH$36.00+1.78%vs close
Mkt Cap$4.17B
Float116.56M
O/S118.04M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Indivior Pharmaceuticals Inc logoNASDAQ:INDV$35.37+0.34%
Phase Distribution
51 lead-sponsored trials·0 active·49 completed
Phase 113
Phase 212
Phase 35
Phase 412
Not applicable9
(7 more as collaborator)
Status Overview
Completed49
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Terminated

    Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)

    buprenorphine, methadone

    Hepatitis C, Chronic

    Enrollment
    128
    Start
    Aug 2005
    Primary Completion
    Feb 2007
    Completion
    Feb 2007
    NCT00279565
  • Phase 4
    Completed

    A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

    Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484, Subutex, Buprenorphine Hydrochloride, SCH 28444

    Opiate Dependence, Drug Dependence

    Enrollment
    241
    Start
    Mar 2008
    Primary Completion
    Apr 2009
    Completion
    May 2009
    NCT00605033
  • Phase 4
    Completed

    Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

    buprenorphine, buprenorphine/naloxone

    Opiate-related Disorders, Opiate Dependence +1

    Enrollment
    60
    Start
    Jul 2007
    Primary Completion
    Dec 2007
    Completion
    Dec 2007
    NCT00684073
  • Phase 4
    Completed

    Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan

    Buprenorphine + naloxone (Suboxone), Buprenorphine + naloxone (Suboxone)

    Opiate Dependence

    Enrollment
    127
    Start
    Mar 2009
    Primary Completion
    Nov 2009
    Completion
    Jan 2010
    NCT00901875
  • Phase 4
    Completed

    Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")

    Buprenorphine (Subutex), Buprenorphine/naloxone (Suboxone)

    Opioid Dependency

    Enrollment
    270
    Start
    Aug 2009
    Primary Completion
    May 2010
    Completion
    May 2011
    NCT00955162
  • Phase 4
    Completed

    Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

    2.0mg Buprenorphine/0.5mg Naloxone, Promethazine

    Hepatic Failure, Hepatic Impairment +1

    Enrollment
    43
    Start
    Sep 2012
    Primary Completion
    Apr 2013
    Completion
    May 2013
    NCT01846455
  • Phase 4
    Completed

    Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

    Suboxone Sublingual Film, Zubsolv sublingual tablets

    Opioid Dependence

    Enrollment
    33
    Start
    Nov 2013
    Primary Completion
    Nov 2013
    Completion
    Nov 2013
    NCT02038790
  • Phase 4
    Completed

    Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

    PERSERIS, Risperidone

    Schizophrenia

    Enrollment
    69
    Start
    Jun 2019
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT03978832
  • Phase 4
    Completed

    SUBLOCADE Rapid Initiation Study

    TM buprenorphine, SUBLOCADE

    Opioid-use Disorder

    Enrollment
    26
    Start
    Aug 2019
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03993392
  • Phase 4
    Completed

    SUBLOCADE Rapid Initiation Extension Study

    Sublocade

    Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate

    Enrollment
    17
    Start
    Oct 2019
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT04060654
  • Phase 4
    Completed

    Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

    Transmucosal Buprenorphine, Extended-release Buprenorphine

    Moderate to Severe Opioid-use Disorder

    Enrollment
    785
    Start
    Oct 2021
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT04995029
  • Phase 4
    Completed

    Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

    Buprenorphine Extended-Release Injection

    Opioid Use Disorder

    Enrollment
    132
    Start
    Mar 2023
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05704543
  • Phase 3
    Completed

    Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

    RBP-7000, Placebo

    Schizophrenia

    Enrollment
    354
    Start
    Apr 2014
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT02109562
  • Phase 3
    Completed

    Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

    RBP-7000

    Schizophrenia

    Enrollment
    500
    Start
    Jun 2014
    Primary Completion
    Sep 2016
    Completion
    Sep 2016
    NCT02203838
  • Phase 3
    Completed

    Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

    SUBOXONE, RBP-6000

    Opioid Dependence, Opioid Related Disorders

    Enrollment
    665
    Start
    Jan 2015
    Primary Completion
    Apr 2016
    Completion
    Apr 2016
    NCT02357901
  • Phase 3
    Completed

    Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

    SUBOXONE sublingual film, RBP-6000

    Opioid Use Disorder, Opioid-related Disorders

    Enrollment
    775
    Start
    Jul 2015
    Primary Completion
    Jan 2017
    Completion
    Jan 2017
    NCT02510014
  • Phase 3
    Completed

    Open-Label Treatment Extension Study

    RBP-6000

    Opioid Use Disorder, Opioid-related Disorders

    Enrollment
    208
    Start
    Aug 2016
    Primary Completion
    Aug 2017
    Completion
    Aug 2017
    NCT02896296
  • Phase 2
    Completed

    Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

    Buprenorphine soluble film, Buprenorphine/naloxone film strip

    Opioid-related Disorders

    Enrollment
    38
    Start
    Mar 2008
    Primary Completion
    Sep 2008
    Completion
    Sep 2008
    NCT00637000
  • Phase 2
    Completed

    Safety and Tolerability of Buprenorphine/Naloxone Film Strips

    Buprenorphine/naloxone Film Strip, Buprenorphine/naloxone Film Strip

    Opioid-Related Disorders

    Enrollment
    382
    Start
    Feb 2008
    Primary Completion
    Oct 2008
    Completion
    Oct 2008
    NCT00640835
  • Phase 2
    Completed

    A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

    XP19986 CR, Placebo for XP19986 CR

    GERD

    Enrollment
    58
    Start
    Oct 2005
    Primary Completion
    Aug 2006
    Completion
    Aug 2006
    NCT00838396
  • Phase 2
    Completed

    Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

    Buprenorphine hydrochloride marketed sublingual tablet (Subutex), Buprenorphine hydrochloride fast dissolving tablet (FDT)

    Opioid Dependency

    Enrollment
    52
    Start
    Sep 2005
    Primary Completion
    Nov 2005
    Completion
    Nov 2005
    NCT01075971
  • Phase 2
    Completed

    Transfer of Subjects From Subutex/Suboxone to RBP-6300

    RBP-6300, Subutex®/Suboxone®

    Opioid Related Disorder

    Enrollment
    143
    Start
    Mar 2012
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01582347
  • Phase 2
    Completed

    Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

    Risperidone, RBP-7000

    Schizophrenia

    Enrollment
    45
    Start
    Aug 2012
    Primary Completion
    Apr 2013
    Completion
    Apr 2013
    NCT01677377
  • Phase 2
    Completed

    Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

    RBP-6000, Subutex

    Opioid Related Disorder

    Enrollment
    124
    Start
    Oct 2012
    Primary Completion
    May 2014
    Completion
    May 2014
    NCT01738503
  • Phase 2
    Completed

    A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

    RBP-8000 100 mg, Placebo

    Opioid Dependence, Opioid Related Disorders +1

    Enrollment
    40
    Start
    Apr 2013
    Primary Completion
    Jun 2013
    Completion
    Jun 2013
    NCT01846481

1-25 of 51

Search ClinicalTrials.gov for “Indivior Pharmaceuticals”